Compounded GLP-1s: what they are, and what actually changed

By The Verendia Editorial Team · Last verified Aug 14, 2026

Short version: A compounded GLP-1 is a semaglutide or tirzepatide preparation made to order by a compounding pharmacy, rather than a mass-manufactured, FDA-approved product. During the national shortage, pharmacies were permitted to compound these widely. That shortage is now resolved — so routine compounding of a copy is restricted, and the lawful path today is a genuinely individualized preparation a licensed provider decides is appropriate for a specific patient. Compounded medications are not FDA-approved, so who prescribes it and which pharmacy makes it matter more than ever.

Verendia is a Better Health partner and earns a commission when you sign up through our links, at no extra cost to you — it never changes what we cover. Educational only, not medical advice; talk to a licensed provider. Full details →

What a GLP-1 medication is

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases after you eat. It helps signal fullness to the brain and slows how quickly the stomach empties. GLP-1 medications are made to mimic that hormone, which is why they’re used in metabolic and weight-management care. How any individual responds — and whether a GLP-1 is appropriate at all — is a clinical question for a licensed provider, not something a webpage can tell you.

Two GLP-1 molecules dominate the conversation: semaglutide and tirzepatide (tirzepatide also acts on a second gut hormone, GIP). Both exist as FDA-approved, brand-name products — and, separately, as compounded preparations. Those two things are not the same, and the difference is the whole point of this guide.

What “compounded” means here

A compounded GLP-1 is a semaglutide or tirzepatide preparation a compounding pharmacy makes to order, rather than a mass-manufactured product that went through FDA approval. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before they’re dispensed.^[4] That doesn’t make them automatically unsafe or illegal — but it does mean the pharmacy that makes it and the provider who prescribes it carry the quality and the judgment, because the FDA’s pre-market check isn’t there. (For the full picture of what compounding is, see our explainer on what “compounded / not FDA-approved” really means.)

What actually changed

For a stretch, compounded GLP-1s were everywhere — because there was an official shortage of the brand-name products. Federal law lets pharmacies compound a copy of a commercially available drug when that drug is in shortage.^[1] That was the legal basis for the wave of compounded semaglutide and tirzepatide.

Then the shortages ended — tirzepatide in late 2024 and semaglutide in early 2025 — and the brand-name products became available again.^[3] When a shortage resolves, the compounding-during-shortage basis goes away, and the rule reverts to the ordinary one: you generally can’t compound something that’s “essentially a copy” of an available approved drug. The FDA has since gone further, proposing not to add semaglutide or tirzepatide to the 503B bulk drug substances list — a signal about how it views ongoing bulk compounding of these molecules.^[2]

So what’s lawful now?

The lawful path narrowed, it didn’t vanish. A compounded GLP-1 today generally has to be a genuinely individualized preparation — one a licensed provider determines is needed for a specific patient’s clinical situation (for example, a documented need that the standard product can’t meet), not a routine copy sold as a cheaper substitute. Price, convenience, or “customization” as a marketing hook don’t meet that bar; a documented, patient-specific clinical reason does. That determination is the provider’s to make — which is exactly why a legitimate GLP-1 path always starts with an evaluation, not an “add to cart.”

How to tell a legitimate source from a risky one

The GLP-1 space drew a lot of sellers during the shortage, and not all of them adjusted when the rules did. A few questions do most of the sorting:

If a source leans on “the shortage” to justify a routine compounded GLP-1 today, that’s outdated — and outdated is a warning sign.

Common side effects to know about

GLP-1 medications — the weight-loss medications at the center of all this — are prescription drugs with real side effects, in any form. The most commonly reported are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which is why providers typically start at a low dose and increase it slowly. Rarer but more serious risks exist too. That’s exactly why a GLP-1, whether an approved product or a compounded drug, is prescription-only — and why a licensed provider should evaluate whether it’s appropriate for you and monitor you while you’re on it, rather than you managing it from a website.

Where a compounded option can still fit

None of this means compounded medicine is bad — our compounding explainer lays out why it’s a legitimate, regulated part of pharmacy. It means the decision moved back where it belongs: with a licensed provider who evaluates you individually, and a state-licensed pharmacy that prepares what’s prescribed. If a provider determines that an approved product is right for you, that’s the straightforward route. If they document that an individualized compounded preparation is appropriate for your situation, that’s a clinical judgment they stand behind — not a marketing claim.

The honest bottom line: the shortage-era “everyone gets compounded semaglutide” moment is over. What’s left is the normal standard of care — get evaluated, and let a licensed provider tell you what’s actually appropriate for you.